SAB Biotherapeutics
SABS
26 hedge funds and large institutions have $2.99M invested in SAB Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 25 → 26 (+1)
4.59% less ownership
Funds ownership: 28.53% → 23.94% (-4.6%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
70% less capital invested
Capital invested by funds: $10.1M → $2.99M (-$7.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
+$59.2K |
| 2 |
SOS
Silver Oak Securities
Jackson,
Tennessee
|
+$46.3K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$38K |
| 4 |
Renaissance Technologies
New York
|
+$23K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.75M |
| 2 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$114K |
| 3 |
Millennium Management
New York
|
-$29.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.31K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.85K |
SABS Hedge Fund Activity: Q1 2025 in Review
26 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2025, worth a combined $2.99M — down 70% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SABS positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 7 trimmed.
The largest buyer was HB Wealth Management, adding an estimated $59.2K. The largest seller was Marshall Wace, exiting entirely with an estimated $1.75M sold.
- 26 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2025, up from 25 in Q4 2024.
- Funds reported $2.99M of SAB Biotherapeutics stock for Q1 2025, down 70% quarter-over-quarter.
- 4 funds opened new SAB Biotherapeutics positions in Q1 2025 and 3 closed out, a net change of +1 holder.
- The largest SAB Biotherapeutics buyer in Q1 2025 was HB Wealth Management, an estimated $59.2K added.
- The largest SAB Biotherapeutics seller in Q1 2025 was Marshall Wace, an estimated $1.75M sold.
Based on aggregated 13F filings for Q1 2025.